Navigation Links
CCPM Issues Statement on FDA's GIVE Initiative
Date:10/4/2007

WASHINGTON, Oct. 5 /PRNewswire-USNewswire/ -- The Coalition for a Competitive Pharmaceutical Market (CCPM) issued the following statement today on the Food and Drug Administration's announcement regarding its "Generic Initiative for Value and Efficiency" (GIVE):

"With consumers, employers, insurers, and policymakers grappling with how to manage escalating prescription drug costs, it is critical that FDA and Congress continue to focus on ways to enhance timely generic access. Today's announcement of the GIVE program by FDA helps focus attention on the need to bolster the generic drug program, but real work remains on important issues that are hindering consumer access. To achieve this, FDA and Congress must address existing issues including the lack of a workable approval pathway for biogenerics, increased funding for the Office of Generic Drugs (OGD) and stopping brand-name pharmaceutical companies from unfairly extending brand drug patents.

"As momentum grows for access to biogenerics, it is imperative that Congress provide FDA with a clear process for facilitating the development and approval of these life-saving medicines that would give patients affordable alternatives to the brand drugs they need. Regulatory and administrative actions are also needed to restructure OGD programs to ensure timely generic access.

"Finally, insufficient OGD funding is slowing the process of getting generic drugs to market. While we welcome FDA's statement that it will hire and train new generic drug reviewers, sufficient funding is needed to make this wish a reality. Substantially increasing resources for OGD is critical to increasing competition in the pharmaceutical market and getting generics into the hands of consumers. We applaud the Senate and House members of the Appropriations Committees for recognizing the importance of sufficient funding and we hope this needed increase is included in the final legislation."

CCPM is an organization of large national employers, health plans, pharmacy benefit managers, chain pharmacies, generic drug manufacturers and others committed to improving consumer access to high quality, affordable generic medicines and promoting a vigorous, competitive prescription drug market.

Contact: Katie Braden Huffard, 202-255-5216


'/>"/>
SOURCE CCPM
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
2. Genomic DNA Preparation from RNAlater Preserved Tissues
3. Preparation of PCR Quality Template DNA from a Wide Range of Tissues Using InstaGene Matrix
4. Using the VersaFluor Fluorometer to Quantitate GUS Expression in Plant Tissues Bombarded With the Biolistic PDS-1000/He System
5. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
6. Genome Wide Profiling of Paired Cancerous and Normal Breast Tissues and Rapid Interpretation of Gene Expression Data
7. Evaluation of RNA isolated from human tissues: quality control for surgical and postmortem samples
8. Genomic Analysis of Formalin-Fixed Paraffin Embedded (FFPE) Tissues through the use of Whole Genome Amplification (WGA)
9. Inline intellectual property raises legal issues
10. SC Johnson issues trademark warning over web offer
11. Company issues warning on outsourced software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):